CST, 65716S, AS-8351

Product Usage Information
AS-8351 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.14 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
AS-8351 is a small-molecule inhibitor of lysine demethylase 5B (JARID1B or KDM5B), which demethylates Lys4 of histone H3. AS-8351 is also involved in cell fate decisions and is overexpressed in a variety of human cancers (1). Overexpression of JARID1B is seen in breast cancer and correlates with increased metastasis. AS-8351 treatment of breast cancer cells inhibited breast cancer cell proliferation and migration. Additionally, AS-8351 reversed epithelial-mesenchymal transition and decreased fatty acid synthase and ATP citrate lyase protein levels in breast cancer cells (2). JARID1B is overexpressed in Ewing sarcoma (EWS) and correlates with poor outcomes in EWS patients. Inhibition of JARID1B by AS-8351 in EWS cells reduced cell proliferation and increased apoptosis and cell cycle arrest. AS-8351 inhibited tumor growth in EWS mouse xenografts, suggesting a possible role for AS-8351 in the clinical treatment of this disease (3).